Engineering topics

Rue, Kelly L.

Publications and source records attributed to Rue, Kelly L..

3 records

DOE OSTI2026

Coordination of Anle138b to Silver Results in Selective Reduction of a C-terminal truncated Alpha-synuclein Protein and Increased Aggregate Size

Parkinson’s disease (PD) is a prevalent age-related neurodegenerative syndrome, partially thought to be caused by a decrease in alpha-synuclein proteostasis. Anle138b = 5-(1,3-benzodioxol-5-yl)-3-(3-bromophenyl)-1H-pyrazole (HL), is undergoing clinical trials as a promising mitigator of alpha-synuclein aggregation. Because complexation to metals is known to modulate the activity of several drugs, we have prepared and characterized: H2L(ClO4), [CuI(µ-L)]3, and [AgI(µ-L)]3. To better understand the bioviability of these compounds, we monitored their effects in a cell culture model of alpha-synuclein protein aggregation using human alpha-synuclein pre-formed fibrils (PFFs). Using two different anti-alpha-synuclein antibodies, our data suggests that [AgI(µ-L)]3 decreases a C-terminal truncated protein that is approximately 12.4 kDa, as well as increases the size and alters the shape of PFF-induced aggregates. This indicates that [AgI(µ-L)]3 impacts aggregation in a manner different from HL and may serve as a novel tool for studying C-terminal truncation related aggregation chemistry.

Rue, Kelly L.↗

DOE OSTI2023

200-DV-1 Laboratory Treatability Study: Proof-of-Principle Results

This document presents the Phase 1 technical approach and results of laboratory-scale treatability testing of nine in situ remedial technologies for their consideration in a future Feasibility Study (FS) for the 200-DV-1 OU. The primary objective of this initial assessment was a proof-of-principle testing evaluation primarily via batch experiments to determine the potential reduction and sequestration of primary contaminants of interest with and without potential co-contaminants of interest. An effectiveness rate of 35% transformation to immobile or nontoxic end products, along with other experimental indicators, was used by the project team to determine the technologies that advanced to Phase 2 for further evaluations. For most technologies, the performance was evaluated based on a series of sequential extractions designed to evaluate the mobility of contaminants before and after treatment, with each subsequent extraction representing a relative decrease in mobility. The results of this study will be used to inform testing for Phase 2 of the treatability study for further evaluation of selected technologies. The final results from the treatability study, following the completion of remaining experimental phases, will be used to determine whether the technologies tested can be appropriately evaluated in a FS to expand on the limited number of viable DVZ remediation technologies. After completion of the laboratory treatability study and the 200-DV-1 OU Remedial Investigation (RI) and Resource Conservation and Recovery Act Facility Investigation (RFI) of the waste sites, results will be evaluated to determine whether field studies are needed to provide additional information on effectiveness, implementability, or costs for evaluating these technologies in the FS for their site-specific application.

12 MANAGEMENT OF RADIOACTIVE AND NON-RADIOACTIVE W↗

DOE OSTI2020

Redox-active dinuclear oxorhenium(V) pyrazolate complexes

Four new structurally similar dinuclear oxorhenium(V) complexes, [{Re(O)X(PPh 3 )} 2 (μ-O)(μ-4-x'-pz) 2 ], where pz = pyrazolate anion, X = X' = Cl (1) and Br (4), X = Cl, X' = Br (2), and X = Br, X' = Cl (3), have been synthesized and characterized. Little variation in spectroscopic features – 1 H NMR, IR, UV–Vis – exists among the four complexes. All complexes possess a bent Re-O-Re core as well as distorted octahedral coordination geometry around the rhenium centers. Finally, a reversible one-electron electrochemical process is observed at approximately 0.84 V vs. Fc + /Fc in all four complexes; however, changing the terminal halide from chloride to bromide slightly destabilizes the oxidized Re(VI) center.

37 INORGANIC, ORGANIC, PHYSICAL, AND ANALYTICAL CH↗